OC
DYN icon

Oppenheimer & Co’s Dyne Therapeutics DYN Stock Holding History

Oppenheimer & Co’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,364
Closed -$144K – 1628
2025
Q3 		$144K Sell
11,364
-23,310
-67% -$266K ﹤0.01% 1587
2025
Q2 		$330K Sell
34,674
-262
-0.7% -$2.88K ﹤0.01% 1311
2025
Q1 		$365K Buy
34,936
+221
+0.6% +$3.16K 0.01% 1190
2024
Q4 		$818K Sell
34,715
-5,376
-13% -$159K 0.01% 880
2024
Q3 		$1.44M Buy
40,091
+1,636
+4% +$65.1K 0.02% 659
2024
Q2 		$1.36M Buy
38,455
+9,926
+35% +$288K 0.02% 657
2024
Q1 		$810K Buy
+28,529
New +$645K 0.01% 817

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Oppenheimer & Co's DYN Position: Q4 2025 in Review

Oppenheimer & Co sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 11,364 shares — an estimated $144K sold.

Oppenheimer & Co first reported a position in DYN in Q1 2024 and held it in 7 quarters. The position peaked at $1.44M in Q3 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Oppenheimer & Co reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 11,364 Dyne Therapeutics shares in Q4 2025, an estimated $144K.
  • Oppenheimer & Co first reported a position in Dyne Therapeutics in Q1 2024 and held it in 7 quarters.
  • Oppenheimer & Co's Dyne Therapeutics position peaked at $1.44M in Q3 2024.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Oppenheimer & Co's 13F filing for Q4 2025, filed 2 Feb 2026.